AAAAAA
Results: 1-25/50
Authors:
Lawrie, LC
Curran, S
McLeod, HL
Fothergill, JE
Murray, GI
Citation: Lc. Lawrie et al., Application of laser capture microdissection and proteomics in colon cancer, J CL PATH-M, 54(4), 2001, pp. 253-258
Authors:
Xu, G
McLeod, HL
Citation: G. Xu et Hl. Mcleod, Strategies for enzyme/prodrug cancer therapy, CLIN CANC R, 7(11), 2001, pp. 3314-3324
Authors:
McLeod, HL
Citation: Hl. Mcleod, Pharmacogenetics: more than skin deep, NAT GENET, 29(3), 2001, pp. 247-248
Authors:
Pritchard, SC
Nicolson, MC
Lloret, C
McKay, JA
Ross, VG
Kerr, KM
Murray, GI
McLeod, HL
Citation: Sc. Pritchard et al., Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: Implications for MMP inhibition therapy, ONCOL REP, 8(2), 2001, pp. 421-424
Authors:
Marsh, S
McKay, JA
Cassidy, J
McLeod, HL
Citation: S. Marsh et al., Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer, INT J ONCOL, 19(2), 2001, pp. 383-386
Authors:
Dusseau, C
Murray, GI
Keenan, RA
O'Kelly, T
Krokan, HE
McLeod, HL
Citation: C. Dusseau et al., Analysis of uracil DNA glycosylase in human colorectal cancer, INT J ONCOL, 18(2), 2001, pp. 393-399
Authors:
Ameyaw, MM
Regateiro, F
Li, T
Liu, XH
Tariq, M
Mobarek, A
Thornton, N
Folayan, GO
Githang'a, J
Indalo, A
Ofori-Adjei, D
Price-Evans, DA
McLeod, HL
Citation: Mm. Ameyaw et al., MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity, PHARMACOGEN, 11(3), 2001, pp. 217-221
Authors:
Kumagai, K
Hiyama, K
Ishioka, S
Sato, H
Yamanishhi, Y
McLeod, HL
Konishi, F
Maeda, H
Yamakido, M
Citation: K. Kumagai et al., Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese, PHARMACOGEN, 11(3), 2001, pp. 275-278
Authors:
McLeod, HL
Evans, WE
Citation: Hl. Mcleod et We. Evans, Pharmacogenomics: Unlocking the human genome for better drug therapy, ANN R PHARM, 41, 2001, pp. 101-121
Authors:
Evans, DAP
McLeod, HL
Pritchard, S
Tariq, M
Mobarek, A
Citation: Dap. Evans et al., Interethnic variability in human drug responses, DRUG META D, 29(4), 2001, pp. 606-610
Authors:
McLeod, HL
Citation: Hl. Mcleod, Race and responsiveness to drugs for heart failure., N ENG J MED, 345(10), 2001, pp. 766-767
Authors:
Balciuniene, J
Syvanen, AC
McLeod, HL
Pettersson, U
Jazin, EE
Citation: J. Balciuniene et al., The geographic distribution of monoamine oxidase haplotypes supports a bottleneck during the dispersion of modern humans from Africa, J MOL EVOL, 52(2), 2001, pp. 157-163
Authors:
Collie-Duguid, ESR
Johnston, SJ
Boyce, L
Smith, N
Cowieson, A
Cassidy, J
Murray, GI
McLeod, HL
Citation: Esr. Collie-duguid et al., Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer, INT J CANC, 94(2), 2001, pp. 297-301
Authors:
Wang, WG
Marsh, S
Cassidy, J
McLeod, HL
Citation: Wg. Wang et al., Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors, CANCER RES, 61(14), 2001, pp. 5505-5510
Authors:
Chapman, AD
Pritchard, SC
Yap, WW
Rooney, PH
Cockburn, JS
Hutcheon, AW
Nicolson, MC
Kerr, KM
McLeod, HL
Citation: Ad. Chapman et al., Primary pulmonary osteosarcoma - Case report and molecular analysis, CANCER, 91(4), 2001, pp. 779-784
Authors:
McFadyen, MCE
Cruickshank, ME
Miller, ID
McLeod, HL
Melvin, WT
Haites, NE
Parkin, D
Murray, GI
Citation: Mce. Mcfadyen et al., Cytochrome P450CYP1B1 over-expression in primary and metastatic ovarian cancer, BR J CANC, 85(2), 2001, pp. 242-246
Authors:
Bissett, D
McLeod, HL
Sheedy, B
Collier, M
Pithavala, Y
Paradiso, L
Pitsiladis, M
Cassidy, J
Citation: D. Bissett et al., Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034, BR J CANC, 84(3), 2001, pp. 308-312
Authors:
McFadyen, MCE
McLeod, HL
Jackson, FC
Melvin, WT
Doehmer, J
Murray, GI
Citation: Mce. Mcfadyen et al., Cytochrome P450CYP1B1 protein expression: a novel mechanism of anticancer drug resistance, BIOCH PHARM, 62(2), 2001, pp. 207-212
Authors:
Ameyaw, MM
Thornton, N
McLeod, HL
Citation: Mm. Ameyaw et al., Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk, J NAT CANC, 92(23), 2000, pp. 1947-1947
Authors:
Curran, S
McKay, JA
McLeod, HL
Murray, GI
Citation: S. Curran et al., Laser capture microscopy, J CL PATH-M, 53(2), 2000, pp. 64-68
Authors:
McLeod, HL
Cassidy, J
Powrie, RH
Priest, DG
Zorbas, MA
Synold, TW
Shibata, S
Spicer, D
Bissett, D
Pithavala, YK
Collier, MA
Paradiso, LJ
Roberts, JD
Citation: Hl. Mcleod et al., Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034, CLIN CANC R, 6(7), 2000, pp. 2677-2684
Authors:
McKay, JA
Douglas, JJ
Ross, VG
Curran, S
Ahmed, FY
Loane, JF
Murray, GI
McLeod, HL
Citation: Ja. Mckay et al., Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases, CLIN CANC R, 6(3), 2000, pp. 1113-1118
Authors:
McKay, JA
Lloret, C
Murray, GI
Johnston, PG
Bicknell, R
Ahmed, FY
Cassidy, J
McLeod, HL
Citation: Ja. Mckay et al., Application of the enrichment approach to identify putative markers of response to 5-fluorouracil therapy in advanced colorectal carcinomas, INT J ONCOL, 17(1), 2000, pp. 153-158
Authors:
Tayeb, MT
Clark, C
Ameyaw, MM
Haites, NE
Evans, DAP
Tariq, M
Mobarek, A
Ofori-Adjei, D
McLeod, HL
Citation: Mt. Tayeb et al., CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations, PHARMACOGEN, 10(8), 2000, pp. 753-756
Authors:
Collie-Duguid, ESR
Etienne, MC
Milano, G
McLeod, HL
Citation: Esr. Collie-duguid et al., Known variant DPYD alleles do not explain DPD deficiency in cancer patients, PHARMACOGEN, 10(3), 2000, pp. 217-223